2 hours ago
The novel oral NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor has indicated its efficacy and safety across 3 clinical trials.
3 hours ago
The FDA has issued a CRL for selective cortisol modulator relacorilant, citing a need for more evidence of effectiveness.
3 hours ago
The FDA has approved oral neurokinin-1 receptor antagonist tradipitant for the prevention of motion sickness, marking the first approval in decades.
1 hour ago
From FDA decisions to late-phase trial readouts and updated practice guidelines, 2025 delivered clinically actionable insights across sleep conditions.
23 hours ago
Catch up on the most impactful headlines in hormonal disorders from all of 2025 with our Year in Review.